Viral broncheolitis treatment
Reading File
Finding Sources
Searching PubMed
bronchiolitis treatment management
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information. Let me compile the answer:
Viral Bronchiolitis: Treatment
Overview
Viral bronchiolitis is the most common lower respiratory tract infection in infants and children under 2 years. RSV accounts for ~70% of cases; rhinovirus, metapneumovirus, parainfluenza, adenovirus, influenza, and human bocavirus are other causes. The disease is self-limiting, typically resolving within 1–3 weeks.
Core Principle: Supportive Care Only
No available treatment shortens the course of bronchiolitis or hastens resolution. Management is entirely supportive.
1. Nasal Suctioning & Saline
The single most important intervention. Upper airway obstruction (mucus, rhinorrhea) is often the primary driver of distress.
- Frequent instillation of nasal saline followed by bulb suctioning
- Provides temporary but meaningful symptomatic relief
2. Oxygen Therapy
- Supplement oxygen when SpO₂ persistently <90% on room air (AAP guideline)
- Continuous monitoring for moderate–severe disease; intermittent for mild disease
- Avoid routine supplemental oxygen in well-compensated infants above this threshold
3. Hydration
- Mild dehydration: smaller, more frequent feeds; pre-feed nasal suctioning
- Significant dehydration or respiratory distress: nasogastric feeds or IV fluids (IV preferred when aspiration risk is high due to tachypnea/retractions)
- SpO₂ and feeding difficulty are the main drivers for hospitalization
4. Respiratory Support (Severe/Hospitalized Cases)
- High-flow nasal cannula (HFNC) — increasingly used for moderate–severe disease
- Nasal CPAP — option for escalating respiratory failure
- Heliox — limited data, used in consultation with critical care
- Intubation and mechanical ventilation — for respiratory failure, recurrent apnea, or cyanosis
Interventions NOT Recommended Routinely
| Intervention | Evidence | Recommendation |
|---|---|---|
| β₂-agonists (albuterol/salbutamol) | No benefit on O₂ sat, hospitalization rate, or LOS | Not routinely recommended |
| Inhaled epinephrine | May offer transient improvement in ED; no reduction in admission rates | Not routine; may be considered in severe/acutely deteriorating disease |
| Corticosteroids (systemic or inhaled) | No benefit in RCTs or Cochrane reviews | Not recommended |
| Dexamethasone + epinephrine (combined) | One Canadian multicenter RCT showed ↓ admissions, but a subsequent meta-analysis did not confirm | Not routine |
| Antibiotics | Risk of bacteremia <1%; no clinical benefit in viral bronchiolitis | Not indicated unless confirmed bacterial coinfection (AOM with bulging TM, consolidation on CXR, positive blood/urine culture) |
| Nebulized hypertonic saline (3% or 7%) | Mixed data; AAP advises against routine ED use | Not recommended routinely |
| Chest physiotherapy | Cochrane review of 3 RCTs: no benefit | Not recommended |
| Ribavirin (aerosolized) | Minimal clinical benefit, toxic effects, high cost | Not recommended routinely; may be considered in high-risk immunocompromised patients with severe RSV |
| Leukotriene inhibitors | No clear evidence of benefit | Not recommended |
Risk Factors for Severe Disease (Consider Admission)
- Prematurity (<37 wk; especially <32 wk)
- Age <2 months
- Underlying cardiac or pulmonary disease
- Immunodeficiency
- SpO₂ ≤91% on room air at triage
- Increased work of breathing (retractions, nasal flaring, grunting)
- Dehydration / poor feeding
- Apnea
RSV Prophylaxis (Prevention, Not Treatment)
Palivizumab (anti-RSV monoclonal antibody) — given prophylactically (not for treatment of active disease):
- Dose: 15 mg/kg IM monthly × 5 doses, starting in autumn
- Indicated in: premature infants (selected cases), hemodynamically significant CHD, chronic lung disease requiring medical therapy, immunosuppression
- Not effective for treatment of established RSV bronchiolitis
Discharge vs. Admission
Most infants can be discharged from the ED. Admit if any of the risk factors above are present or if there are social concerns and inadequate follow-up. Counsel parents that symptoms may persist up to 3 weeks to reduce unnecessary return visits for mild persistent symptoms.
Sources:
- Tintinalli's Emergency Medicine, block 10
- Swanson's Family Medicine Review, block 5
- Murray & Nadel's Textbook of Respiratory Medicine, block 17
- Red Book 2021 (AAP Committee on Infectious Diseases), block 5
Recent evidence (2024): Two systematic reviews confirm supportive care remains standard; HFNC use in bronchiolitis is an evolving area (PMID 38902454, PMID 39690333).
This is a shared conversation. Sign in to Orris to start your own chat.